# Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)

> **NCT04402385** · PHASE2 · TERMINATED · sponsor: **Yale University** · enrollment: 50 (actual)

## Conditions studied

- Pre-Eclampsia
- Stage 1 Hypertension
- Elevated Blood Pressure

## Interventions

- **DRUG:** Aspirin 81 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04402385
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-08-06
- **Primary completion:** 2022-06-22
- **Final completion:** 2022-06-22
- **Target enrollment:** 50 (ACTUAL)
- **Why stopped:** Unable to recruit.
- **Last updated:** 2023-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04402385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04402385, "Aspirin to Prevent Preeclampsia in Women With Elevated Blood Pressure and Stage 1 Hypertension (ASPPIRE)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04402385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*